Medical Services International Inc.

Medical Services International Inc.

MSITF
Medical Services International Inc.US flagOther OTC
0.00
USD
- -
- -
480,000.00Market Cap
Medical Services International Inc.
MSITF
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available
Business
Medical Services International Inc. (MSITF) designs, manufactures, and sells medical devices primarily focused on diagnostic and testing equipment for infectious diseases; its core products include the MSRapid line of point-of-care diagnostic tests for HIV, Hepatitis C, and other rapid screening assays, alongside automated immunoassay analyzers and related consumables such as test kits and reagents. The company operates in the healthcare diagnostics segment, targeting clinical laboratories, hospitals, blood banks, and point-of-care settings in emerging and developed markets across North America, Asia, Africa, and Latin America. Founded in 1996 and headquartered in Toronto, Canada, the company maintains manufacturing facilities in Canada and distribution networks through strategic partnerships in multiple regions. In recent developments within the last two years, Medical Services International Inc. expanded its product portfolio with the launch of next-generation MSRapid multiplex tests for simultaneous detection of multiple pathogens, enhancing efficiency in resource-limited settings; it also secured a significant distribution agreement with a major Asian healthcare distributor in 2024 to broaden market penetration in Southeast Asia and announced plans for a new production line dedicated to tuberculosis diagnostics amid rising global demand.